Donor and recipient treatment with the Lazaroid U-74006F do not improve post-transplant lung function in swine.
OBJECTIVE
U-74006F is the only Lazaroid which is currently in clinical use. A number of experimental studies demonstrate that Lazaroids reduce ischemia/reperfusion injury in various organ systems. We evaluated the effect of U-74006F on reperfusion injury in a large animal model of lung allo-transplantation.


METHODS
Two different treatment modalities were evaluated and compared with corresponding control groups. Unilateral left lung transplantation was performed in 21 weight-matched pigs (24-31 kg). Donor lungs were flushed with 1.51 cold (1 degrees C) LPD solution and preserved for 20 h. In group I (n = 5), donor animals were pretreated with U-74006F (10 mg/ kg i.v.) 20 min before harvest. In addition U-74006F was added to the flush solution (10 mg/l). In group III (n = 6), the Lazaroid was given to the donor before flush and to the recipient before reperfusion (3 mg/kg i.v.). Group II and IV (n = 5) served as control. One hour after reperfusion, the recipient contralateral right pulmonary artery and bronchus were ligated to assess graft function only. Extravascular lung water index (EVLWI), mean pulmonary artery pressure, cardiac output, and gas exchange were assessed during a 5 h observation period. Lipid peroxidation (TBARS) and neutrophil migration (MPO activity) were measured at the end of the assessment in lung allograft tissue.


RESULTS
A significant change of TBARS concentration was shown in group III (group III 78.7+/-4.6 pmol/g vs. group IV 120.8+/-7.2 pmol/g (P = 0.0065) normal lung tissue 41.3+/-4.2 pmol/g). MPO activity was reduced in group III 3.74+/-0.25 deltaOD/mg per min vs. group IV 4.97+/-0.26 deltaOD/mg per min (P = 0.027), normal lung tissue 1.04+/-0.27 deltaOD/mg per min). Pulmonary hemodynamics and gas exchange after reperfusion did not differ between groups. In group I and III, a tendency towards a reduced EVLWI was noted.


CONCLUSIONS
We conclude that combined treatment of donor and recipient with U-74006F reduces free radical mediated injury in the allograft. However, this intervention did not result in a significant reduction of post-transplant lung edema or improvement of pulmonary hemodynamics. Donor pretreatment alone did not improve lung allograft reperfusion injury. These results indicate that the benefit of U-74006F is too small to consider clinical application in lung transplantation.
Hillinger
S
S
Department of Surgery, University Hospital, Zürich, Switzerland.
Schmid
R A
RA
Stammberger
U
U
Boehler
A
A
Schöb
O M
OM
Zollinger
A
A
Weder
W
W
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D004195:Disease Models, Animal; D015633:Extravascular Lung Water; D016166:Free Radical Scavengers / Q000627:therapeutic use*; D008168:Lung / Q000473:pathology; D016040:Lung Transplantation; D011183:Postoperative Complications / Q000517:prevention & control*; D011281:Pregnatrienes / Q000627:therapeutic use*; D011654:Pulmonary Edema / Q000517:prevention & control; D015427:Reperfusion Injury / Q000517:prevention & control*; D013552:Swine; D014184:Transplantation, Homologous
D000975:Antioxidants; D016166:Free Radical Scavengers; D011281:Pregnatrienes; C053355:tirilazad